Johnson & Johnson Other Long-Term Assets 2012-2026 | JNJ
Johnson & Johnson other long-term assets from 2012 to 2026. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Johnson & Johnson other long-term assets for the quarter ending March 31, 2026 were $14.368B, a 25.88% increase year-over-year.
- Johnson & Johnson other long-term assets for 2025 were $14.368B, a 25.88% increase from 2024.
- Johnson & Johnson other long-term assets for 2024 were $11.414B, a 19.35% decline from 2023.
- Johnson & Johnson other long-term assets for 2023 were $14.153B, a 53.64% increase from 2022.
|
Johnson & Johnson Annual Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2025 | $14,368 |
| 2024 | $11,414 |
| 2023 | $14,153 |
| 2022 | $9,212 |
| 2021 | $10,216 |
| 2020 | $6,562 |
| 2019 | $5,695 |
| 2018 | $4,182 |
| 2017 | $4,971 |
| 2016 | $4,435 |
| 2015 | $4,413 |
| 2014 | $3,232 |
| 2013 | $4,949 |
| 2012 | $3,417 |
| 2011 | $3,773 |
|
Johnson & Johnson Quarterly Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2025-12-31 | $14,368 |
| 2025-09-30 | $12,416 |
| 2025-06-30 | $12,189 |
| 2025-03-31 | $11,534 |
| 2024-12-31 | $11,414 |
| 2024-09-30 | $10,921 |
| 2024-06-30 | $10,544 |
| 2024-03-31 | $14,125 |
| 2023-12-31 | $14,153 |
| 2023-09-30 | $13,133 |
| 2023-06-30 | $10,078 |
| 2023-03-31 | $9,567 |
| 2022-12-31 | $9,212 |
| 2022-09-30 | $8,625 |
| 2022-06-30 | $9,435 |
| 2022-03-31 | $9,939 |
| 2021-12-31 | $10,216 |
| 2021-09-30 | $6,870 |
| 2021-06-30 | $7,172 |
| 2021-03-31 | $6,538 |
| 2020-12-31 | $6,562 |
| 2020-09-30 | $6,131 |
| 2020-06-30 | $5,782 |
| 2020-03-31 | $5,042 |
| 2019-12-31 | $5,695 |
| 2019-09-30 | $5,307 |
| 2019-06-30 | $5,430 |
| 2019-03-31 | $5,159 |
| 2018-12-31 | $4,182 |
| 2018-09-30 | $4,465 |
| 2018-06-30 | $4,421 |
| 2018-03-31 | $4,518 |
| 2017-12-31 | $4,971 |
| 2017-09-30 | $5,021 |
| 2017-06-30 | $5,273 |
| 2017-03-31 | $4,690 |
| 2016-12-31 | $4,435 |
| 2016-09-30 | $4,245 |
| 2016-06-30 | $3,977 |
| 2016-03-31 | $4,163 |
| 2015-12-31 | $4,413 |
| 2015-09-30 | $3,804 |
| 2015-06-30 | $3,855 |
| 2015-03-31 | $3,605 |
| 2014-12-31 | $3,232 |
| 2014-09-30 | $5,033 |
| 2014-06-30 | $6,435 |
| 2014-03-31 | $6,459 |
| 2013-12-31 | $4,949 |
| 2013-09-30 | $2,715 |
| 2013-06-30 | $2,477 |
| 2013-03-31 | $3,723 |
| 2012-12-31 | $3,417 |
| 2012-09-30 | $3,521 |
| 2012-06-30 | $3,891 |
| 2012-03-31 | $3,956 |
| 2011-12-31 | $3,773 |
| 2011-09-30 | $3,905 |
| 2011-06-30 | $4,193 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |